首页> 外文期刊>The Quarterly Journal of Nuclear Medicine >Detection of myocardial viability with ~(99m)Tc-labelled myocardial perfusion agents
【24h】

Detection of myocardial viability with ~(99m)Tc-labelled myocardial perfusion agents

机译:〜(99m)Tc标记的心肌灌注剂检测心肌活力

获取原文
获取原文并翻译 | 示例
           

摘要

Detection of myocardial viability is an important clinical issue in the time course of acute myocardial infarction and in chronic coronary artery disease. The wide availability of myocardial revasculariza-tion procedures requires a refinement of specific indications for revascularization whenever left ventricular failure is the most prominent feature of coronary artery disease. In this instance the risk/benefit ratio has to be attentively evaluated with diagnostic tests able to predict favourable changes in regional and global left ventricular function, symptoms, life quality, risk of adverse events and ultimately prognosis. 201 x 1 has been shown to provide clinically televant information regarding the presence of myocardial viability in patients with extensive regional or global ventricular dysfunction. However, the increasing use of ~(99m)Tc labeled myocardial perfusion agents requires a careful evaluation of diagnostic and predictive accuracy of these agents also for the issue of myocardial viability. The widely accepted opinion of a lower predictive accuracy of these agents compared to 201 x 1 could be no longer true. The available clinical and experimental data indicate, at least for ~(99m)Tc-sestamibi, a comparable accuracy when independent and clinically relevant gold standard of viability like post-revascular-ization functional recovery is considered. Preliminary data indicate that protocols, like nitrate administration, slow infusion or delayed imaging, and accurate quantitation of ~(99m)Tc-sestamibi SPECT studies could enhance the predictive accuracy to a level comparable or even better than that of ~(201)T1 and similar to the more demanding PET technology.
机译:在急性心肌梗塞和慢性冠状动脉疾病的病程中,心肌存活力的检测是重要的临床问题。只要左心衰竭是冠状动脉疾病的最突出特征,心肌血运重建程序的广泛可用性就需要对血运重建的具体适应症进行完善。在这种情况下,必须用能够预测区域和整体左心室功能,症状,生活质量,不良事件风险和最终预后的有利变化的诊断测试来认真评估风险/收益比。已显示201 x 1可提供有关广泛的区域性或整体性心室功能不全患者心肌生存能力的临床远程信息。但是,〜(99m)Tc标记的心肌灌注剂的使用日益增加,还需要仔细评估这些药物的诊断和预测准确性,同时也要解决心肌生存问题。与201 x 1相比,这些药物的预测准确性较低的广泛接受的观点可能不再正确。可用的临床和实验数据表明,至少对于〜(99m)Tc-sestamibi,当考虑独立的和临床相关的生存力金标准(如血管重建后功能恢复)时,其准确性可比。初步数据表明,如硝酸盐管理,缓慢输注或延迟成像以及对〜(99m)Tc-司他他比SPECT研究进行准确定量的方案可以将预测准确性提高到与〜(201)T1和类似于要求更高的PET技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号